Австралія - англійська - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - bimatoprost, quantity: 300 microgram/ml - eye drops, solution - excipient ingredients: citric acid monohydrate; sodium chloride; dibasic sodium phosphate heptahydrate; hydrochloric acid; sodium hydroxide; purified water - lumigan pf is indicated for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta-blockers

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

apotex nz ltd - bimatoprost 0.3 mg/ml;   - eye drops, solution - 0.3 mg/ml - active: bimatoprost 0.3 mg/ml   excipient: benzalkonium chloride citric acid dibasic sodium phosphate hydrochloric acid sodium chloride sodium hydroxide - apo-bimatoprost is indicated as a monotherapy for the reduction of elevated intraocular pressure (iop) in patients with chronic glaucoma or ocular hypertension; or as adjunctive therapy in patients not adequately controlled on other agents.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - bimatoprost, quantity: 300 microgram/ml - eye drops - excipient ingredients: sodium hydroxide; hydrochloric acid; dibasic sodium phosphate; benzalkonium chloride; citric acid monohydrate; water for injections; sodium chloride - bimtop is indicated for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta- blockers.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - bimatoprost -

США - англійська - NLM (National Library of Medicine)

alembic pharmaceuticals limited - bimatoprost (unii: qxs94885mz) (bimatoprost - unii:qxs94885mz) - bimatoprost ophthalmic solution, 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness. bimatoprost ophthalmic solution, 0.03% is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients [see adverse reactions 6.2) ]. risk summary there are no adequate and well-controlled studies of bimatoprost ophthalmic solution 0.03% administration in pregnant women. there is no increase in the risk of major birth defects or miscarriages based on bimatoprost postmarketing experience. in embryofetal development studies, administration of bimatoprost to pregnant mice and rats during organogenesis resulted in abortion and early delivery at oral doses at least 33 times (mice) or 94 times (rats) the human exposure following topical ophthalmic administration of bimatoprost 0.03% to the cornea or conjunctival sac bilaterally once daily, based on the area under the curve (auc). these adverse effects were not observ

США - англійська - NLM (National Library of Medicine)

alembic pharmaceuticals limited - bimatoprost (unii: qxs94885mz) (bimatoprost - unii:qxs94885mz) - bimatoprost ophthalmic solution, 0.03% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.  bimatoprost ophthalmic solution, 0.03% is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients [see adverse reactions (6.2) ]. risk summary there are no adequate and well-controlled studies of bimatoprost ophthalmic solution, 0.03% administration in pregnant women. there is no increase in the risk of major birth defects or miscarriages based on bimatoprost postmarketing experience. in embryofetal developmental studies, administration of bimatoprost in pregnant mice and rats during organogenesis, resulted in abortion and early delivery at oral doses at least 33 times (mice) or 94 times (rats) the human exposure at the recommended clinical dose (based on blood area under the curve [auc] levels). these adverse effects were not observed at 2.6 times (mice) and 47 times (rats) the human exposure at the

Канада - англійська - Health Canada

apotex inc - bimatoprost - solution - 0.03% - bimatoprost 0.03% - prostaglandin analogs

Канада - англійська - Health Canada

apotex inc - bimatoprost - solution - 0.03% - bimatoprost 0.03% - prostaglandin analogs

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - bimatoprost, quantity: 0.3 mg/ml - eye drops, solution - excipient ingredients: citric acid; sodium hydroxide; dibasic sodium phosphate; benzalkonium chloride; sodium chloride; water for injections; hydrochloric acid - the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta-blockers.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - bimatoprost, quantity: 0.3 mg/ml - eye drops, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide; citric acid monohydrate; sodium chloride; dibasic sodium phosphate heptahydrate; benzalkonium chloride - bimatoprost is indicated for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta-blockers.